Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Proton3on Oct 01, 2021 4:03pm
120 Views
Post# 33953834

RE:ARISTOTLE and STAGEZERO

RE:ARISTOTLE and STAGEZEROYou are clearly new and inexperienced here and for sure was not around when they were trying to sell Colonsentry a very similar product and everyone was saying similar thing that you are now. Lets see, Photoman says 50 test per day, times 90 days in a quarter, equals 4500 test. Isn't their entire customer base only 10,000? That means at this rate they will have to test 50% for all their customers in 1 Q lol and run out of them after 2 quarters. This prediction might be as bad as Tripp's 30 million in 2019 and finishing with 140K lol.

If they can sell 300+ total tests in a quarter it would be good for their standards to start. Not sure how many people want to pay 1500$ for an experiemental new cancer test never really used. I would say "hell no" if they offered this to me and ask what are the normal standard options. People like you just blindly think things will majically turn out well its crazy especially with the horrific history here.

Invest your whole life saving in this junk be my guest, but dont run around writing things you have no reason to other than pure optimism, because here it has cost many shareholders a ton of money. Look what happened to Gojo, he tripled up 1.10. Cape, Lith, Jonny (thats you) are all stuck big time bagholders by blindly believing Tripp and IR.
<< Previous
Bullboard Posts
Next >>